Citigroup’s Theriva Biologics TOVX Stock Holding History

Citigroup’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$272	Sell	1,391 -4,798	-78%	-$946	﹤0.01%	5562
2025 Q4	$1.3K	Buy	6,189 +6,188	+618,800%	+$1.83K	﹤0.01%	5519
2025 Q3	$0	Buy	+1	New	–	﹤0.01%	6323
2025 Q1	–	Sell	-7,756	Closed	-$13.6K	–	5966
2024 Q4	$13.6K	Buy	+7,756	New	+$11.3K	﹤0.01%	5321
2018 Q4	–	Hold	0	–	–	–	7836
2018 Q3	–	Hold	0	–	–	–	7868
2018 Q2	–	Hold	0	–	–	–	7738
2018 Q1	–	Hold	0	–	–	–	7674
2017 Q4	–	Hold	0	–	–	–	7497
2017 Q3	–	Hold	0	–	–	–	7158
2017 Q2	–	Hold	0	–	–	–	7204
2017 Q1	–	Sell	-11	Closed	-$76.7K	–	7107
2016 Q4	$75K	Buy	11 +10	+1,000%	+$103K	﹤0.01%	5946
2016 Q3	$12K	Hold	1	–	–	﹤0.01%	6467
2016 Q2	$15K	Buy	+1	New	+$18.8K	﹤0.01%	6327
2016 Q1	–	Hold	0	–	–	–	7339
2015 Q4	–	Hold	0	–	-$3K	–	7864
2015 Q3	–	Hold	0	–	–	–	6936
2015 Q2	–	Hold	0	–	–	–	6575
2015 Q1	–	Hold	0	–	–	–	7078
2014 Q4	–	Hold	0	–	–	–	6741
2014 Q3	–	Hold	0	–	–	–	7299
2014 Q2	–	Hold	0	–	–	–	6959
2014 Q1	–	Hold	0	–	–	–	6895
2013 Q4	–	Hold	0	–	–	–	6792
2013 Q3	–	Hold	0	–	–	–	6537
2013 Q2	–	Hold	0	–	–	–	6460

Other funds holding TOVX

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Citigroup's TOVX Position: Q1 2026 in Review

Citigroup reduced its Theriva Biologics (TOVX) stake by 78% in Q1 2026, selling an estimated $946 and leaving 1,391 shares worth $272. The position accounts for ﹤0.01% of the portfolio, ranked #5562.

Citigroup first reported a position in TOVX in Q2 2016 and has held it in 7 quarters since. The position peaked at $75K in Q4 2016. 22 funds tracked by Wall St. Rank hold TOVX as of Q1 2026.

Citigroup held 1,391 shares of Theriva Biologics worth $272 as of Q1 2026.
Citigroup sold 4,798 Theriva Biologics shares in Q1 2026, an estimated $946.
Theriva Biologics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5562 holding.
Citigroup first reported a position in Theriva Biologics in Q2 2016 and has held it in 7 quarters since.
Citigroup's Theriva Biologics position peaked at $75K in Q4 2016.
22 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.